We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Ultra-Fast COVID-19 PCR Test to Achieve High Accuracy at Speed 20 Times Faster than Lab-Based PCR Tests

By LabMedica International staff writers
Posted on 22 Nov 2021
Print article
Image: MolDx Analyzer (Photo courtesy of miDIAGNOSTICS)
Image: MolDx Analyzer (Photo courtesy of miDIAGNOSTICS)

An ultra-fast COVID-19 PCR test developed for point-of-care use combines the accuracy of central lab-based PCR testing with the speed of self-testing.

miDIAGNOSTICS (Leuven, Belgium) has developed a rapid COVID-19 PCR test that has the potential to achieve an excellent accuracy at a speed 20 times faster than ‘classic’ PCR machines in labs. The test, based on the company’s highly innovative diagnostics platform, involves the transfer of a nasopharyngeal swab sample on a PCR test card, from which the results are read by a compact reader.

The COVID-19 pandemic has underscored the importance of abundant and accurate diagnostics. It will still take quite some time before herd immunity will be achieved worldwide, and ongoing virus mutations and new variants pose major challenges to the vaccination process. Meanwhile, there is a great need for rapid accurate tests that can be performed at airports, in the workplace, at events, in doctors’ offices, or even at home. Unfortunately, rapid COVID-19 tests often have limited accuracy, while reliable diagnostic tests, based on PCR analysis and performed in central laboratories, can take anywhere from several hours to several days from a sample collection to a test result.

Enabled by miDIAGNOSTICS’ silicon chip technology, its ultra-fast PCR COVID-19 test combines the speed of a rapid antigen test with the performance of trusted PCR-based testing. The company’s ultra-fast COVID-19 PCR test will take 15 minutes from sample to result. Testing can be easily scaled up with the combination of multiple readers, because of the short turnaround time of 15 minutes, enabling simultaneous high throughput in many decentralized settings where highly accurate testing is desired, including at airports, offices, schools, events or any other local healthcare setting. Beyond COVID-19, the platform has the potential to be reconfigured for diagnosing other infectious diseases, as needed.

Related Links:
miDIAGNOSTICS 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.